Search

SYSTIMMUNE Antibody-Drug Conjugate Patent with Acidic Stabilization Junction

The USPTO granted Patent US12605458B2 to SYSTIMMUNE, Inc. on April 21, 2026, covering an antibody-drug conjugate with a hydrophilic acidic stabilization junction designed to maintain desired pharmacokinetic properties at higher drug loading. The patent, filed June 15, 2018, contains 18 claims and is classified under multiple therapeutic CPC codes including A61P 35/00 (anti-neoplastic), A61P 29/00 (anti-inflammatory), and A61P 37/02 (immunomodulators).